This course will review the latest revisions to the American Diabetes Association (ADA) Standards of Care specifically highlighting the rising rates of obesity related to diabetes, a pressing health concern affecting millions worldwide and often referred to as “diabesity.” Learners will gain insights into nuances related to medication management and therapeutic decision-making for patients with diabetes. Content will provide guidance for reviewing and crafting patient-centered treatment strategies that holistically address glucose management while fostering improvements in cardiometabolic, kidney, liver, and cognitive health for individuals grappling with diabetes and related comorbidities.

Upon successful completion of this application-based CPE course, pharmacists should be able to:
1. Summarize recent changes to the American Diabetes Association Management of Hyperglycemia in type 1 and type 2 diabetes.
2. Discuss the rationale regarding therapeutic decision-making when selecting medication therapy for people with type 2 diabetes and its multi-morbidities.
3. Formulate patient-centered treatment plans for people with diabetes to reduce glucose, and improve cardiometabolic, kidney, liver, and cognitive health.

Susan Cornell, PharmD, CDCES, FAPhA, FADCES
Professor, Pharmacy Practice
Diabetes Care & Education Specialist
Midwestern University College of Pharmacy

Dr. Susan Cornell is an advisory board member for Novo Nordisk. All relevant financial relationships have been mitigated.

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: February 13, 2024
Planned Expiration Date: February 13, 2027

Copyright 2024, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.